Toll Free: 1-888-928-9744
Published: Jan, 2015 | Pages:
154 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Squamous Non-Small Cell Lung Cancer - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Squamous Non-Small Cell Lung Cancer - Pipeline Review, H1 2015', provides an overview of the Squamous Non-Small Cell Lung Cancer's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Squamous Non-Small Cell Lung Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Squamous Non-Small Cell Lung Cancer and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Squamous Non-Small Cell Lung Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Squamous Non-Small Cell Lung Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Squamous Non-Small Cell Lung Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Squamous Non-Small Cell Lung Cancer pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons To Buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Squamous Non-Small Cell Lung Cancer - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Squamous Non-Small Cell Lung Cancer pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Squamous Non-Small Cell Lung Cancer Overview 9 Therapeutics Development 10 Pipeline Products for Squamous Non-Small Cell Lung Cancer - Overview 10 Pipeline Products for Squamous Non-Small Cell Lung Cancer - Comparative Analysis 11 Squamous Non-Small Cell Lung Cancer - Therapeutics under Development by Companies 12 Squamous Non-Small Cell Lung Cancer - Therapeutics under Investigation by Universities/Institutes 15 Squamous Non-Small Cell Lung Cancer - Pipeline Products Glance 16 Late Stage Products 16 Clinical Stage Products 17 Early Stage Products 18 Squamous Non-Small Cell Lung Cancer - Products under Development by Companies 19 Squamous Non-Small Cell Lung Cancer - Products under Investigation by Universities/Institutes 21 Squamous Non-Small Cell Lung Cancer - Companies Involved in Therapeutics Development 22 AbbVie Inc. 22 Advenchen Laboratories, LLC 23 Ascenta Therapeutics, Inc. 24 AstraZeneca PLC 25 Bayer AG 26 Boehringer Ingelheim GmbH 27 Bristol-Myers Squibb Company 28 Celgene Corporation 29 Eisai Co., Ltd. 30 Eli Lilly and Company 31 F. Hoffmann-La Roche Ltd. 32 Five Prime Therapeutics, Inc. 33 Genentech, Inc. 34 Johnson & Johnson 35 Novartis AG 36 Oncogenex Pharmaceuticals, Inc. 37 Ono Pharmaceutical Co., Ltd. 38 Vertex Pharmaceuticals Incorporated 39 Squamous Non-Small Cell Lung Cancer - Therapeutics Assessment 40 Assessment by Monotherapy Products 40 Assessment by Target 41 Assessment by Mechanism of Action 44 Assessment by Route of Administration 46 Assessment by Molecule Type 48 Drug Profiles 50 ABT-414 - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 apatorsen - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 AT-406 - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 AZD-8186 - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 BAY-1163877 - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 BMS-833923 - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 BMS-906024 - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 buparlisib hydrochloride - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 FP-1039 - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 ipilimumab - Drug Profile 69 Product Description 69 Mechanism of Action 69 R&D Progress 69 JNJ-42756493 - Drug Profile 73 Product Description 73 Mechanism of Action 73 R&D Progress 73 lenvatinib - Drug Profile 75 Product Description 75 Mechanism of Action 75 R&D Progress 75 lucitanib - Drug Profile 79 Product Description 79 Mechanism of Action 79 R&D Progress 79 lumretuzumab - Drug Profile 81 Product Description 81 Mechanism of Action 81 R&D Progress 81 LY-2606368 - Drug Profile 83 Product Description 83 Mechanism of Action 83 R&D Progress 83 LY-3023414 - Drug Profile 84 Product Description 84 Mechanism of Action 84 R&D Progress 84 necitumumab - Drug Profile 86 Product Description 86 Mechanism of Action 86 R&D Progress 86 nintedanib - Drug Profile 89 Product Description 89 Mechanism of Action 89 R&D Progress 89 nivolumab (recombinant) - Drug Profile 93 Product Description 93 Mechanism of Action 93 R&D Progress 93 paclitaxel albumin bound - Drug Profile 98 Product Description 98 Mechanism of Action 98 R&D Progress 98 pictilisib - Drug Profile 102 Product Description 102 Mechanism of Action 102 R&D Progress 102 Small Molecule to Inhibit TWIST1 for Non-Small Cell Lung Cancer - Drug Profile 104 Product Description 104 Mechanism of Action 104 R&D Progress 104 veliparib - Drug Profile 105 Product Description 105 Mechanism of Action 105 R&D Progress 105 VX-970 - Drug Profile 108 Product Description 108 Mechanism of Action 108 R&D Progress 108 Squamous Non-Small Cell Lung Cancer - Recent Pipeline Updates 109 Squamous Non-Small Cell Lung Cancer - Dormant Projects 145 Squamous Non-Small Cell Lung Cancer - Discontinued Products 146 Squamous Non-Small Cell Lung Cancer - Product Development Milestones 147 Featured News & Press Releases 147 Jan 11, 2015: CheckMate -017, A Phase 3 Study of Opdivo (Nivolumab) Compared to Docetaxel in Patients with Second-Line Squamous Cell Non-small Cell Lung Cancer, Stopped Early 147 Oct 30, 2014: Phase 2 Objective Response Rate and Survival Data for Opdivo (nivolumab) in Heavily Pre-treated Advanced Squamous Cell Non-Small Cell Lung Cancer to be Presented at the 2014 Chicago Multidisciplinary Symposium on Thoracic Oncology 147 Oct 23, 2014: Clovis Oncology Announces First Patient Enrolled in Lucitanib Phase 2 Study in Squamous Non-small Cell Lung Cancer 149 Jul 01, 2014: OncoGenex Announces Cedar Clinical Trial Evaluating Apatorsen in Combination with Chemotherapy in Advanced Squamous Cell Lung Cancer is Now Open for Enrollment 150 May 14, 2014: Clovis Oncology Announces Clinical Data Of Lucitanib to Be Presented at 2014 ASCO Annual Meeting 150 Aug 13, 2013: Eli Lilly and Company's Phase III study of necitumumab meets primary endpoint 151 Jun 04, 2013: Debiopharm Announces Additional Phase I Clinical Trial Evaluating Debio 1143 Combined With Chemotherapies For Patients With Selected Solid Malignancies 151 May 23, 2013: OncoGenex Pharma Announces Plans For Initiation Of Cedar Clinical Trial Evaluating OGX-427 In Combination With Chemotherapy In Advanced Squamous Cell Lung Cancer 152 Appendix 153 Methodology 153 Coverage 153 Secondary Research 153 Primary Research 153 Expert Panel Validation 153 Contact Us 154 Disclaimer 154
List of Tables Number of Products under Development for Squamous Non-Small Cell Lung Cancer, H1 2015 10 Number of Products under Development for Squamous Non-Small Cell Lung Cancer - Comparative Analysis, H1 2015 11 Number of Products under Development by Companies, H1 2015 13 Number of Products under Development by Companies, H1 2015 (Contd..1) 14 Number of Products under Investigation by Universities/Institutes, H1 2015 15 Comparative Analysis by Late Stage Development, H1 2015 16 Comparative Analysis by Clinical Stage Development, H1 2015 17 Comparative Analysis by Early Stage Development, H1 2015 18 Products under Development by Companies, H1 2015 19 Products under Development by Companies, H1 2015 (Contd..1) 20 Products under Investigation by Universities/Institutes, H1 2015 21 Squamous Non-Small Cell Lung Cancer - Pipeline by AbbVie Inc., H1 2015 22 Squamous Non-Small Cell Lung Cancer - Pipeline by Advenchen Laboratories, LLC, H1 2015 23 Squamous Non-Small Cell Lung Cancer - Pipeline by Ascenta Therapeutics, Inc., H1 2015 24 Squamous Non-Small Cell Lung Cancer - Pipeline by AstraZeneca PLC, H1 2015 25 Squamous Non-Small Cell Lung Cancer - Pipeline by Bayer AG, H1 2015 26 Squamous Non-Small Cell Lung Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2015 27 Squamous Non-Small Cell Lung Cancer - Pipeline by Bristol-Myers Squibb Company, H1 2015 28 Squamous Non-Small Cell Lung Cancer - Pipeline by Celgene Corporation, H1 2015 29 Squamous Non-Small Cell Lung Cancer - Pipeline by Eisai Co., Ltd., H1 2015 30 Squamous Non-Small Cell Lung Cancer - Pipeline by Eli Lilly and Company, H1 2015 31 Squamous Non-Small Cell Lung Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 32 Squamous Non-Small Cell Lung Cancer - Pipeline by Five Prime Therapeutics, Inc., H1 2015 33 Squamous Non-Small Cell Lung Cancer - Pipeline by Genentech, Inc., H1 2015 34 Squamous Non-Small Cell Lung Cancer - Pipeline by Johnson & Johnson, H1 2015 35 Squamous Non-Small Cell Lung Cancer - Pipeline by Novartis AG, H1 2015 36 Squamous Non-Small Cell Lung Cancer - Pipeline by Oncogenex Pharmaceuticals, Inc., H1 2015 37 Squamous Non-Small Cell Lung Cancer - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2015 38 Squamous Non-Small Cell Lung Cancer - Pipeline by Vertex Pharmaceuticals Incorporated, H1 2015 39 Assessment by Monotherapy Products, H1 2015 40 Number of Products by Stage and Target, H1 2015 42 Number of Products by Stage and Mechanism of Action, H1 2015 45 Number of Products by Stage and Route of Administration, H1 2015 47 Number of Products by Stage and Molecule Type, H1 2015 49 Squamous Non-Small Cell Lung Cancer Therapeutics - Recent Pipeline Updates, H1 2015 109 Squamous Non-Small Cell Lung Cancer - Dormant Projects, H1 2015 145 Squamous Non-Small Cell Lung Cancer - Discontinued Products, H1 2015 146
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.